Stable pharmaceutical compositions of a cyp11a1 inhibitor
EP4746854A1Pending Publication Date: 2026-05-27ORION CORP(FI)
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- ORION CORP(FI)
- Filing Date
- 2024-07-17
- Publication Date
- 2026-05-27
AI Technical Summary
Technical Problem
The compound 2-(isoindolin-2-ylmethyl)-5-((l-(methylsulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one (I) and its salts are prone to stability issues when formulated with carriers and excipients for solid oral compositions, such as tablets and capsules.
Method used
Incorporating a stability-enhancing amount of a pharmaceutically acceptable organic acid, such as citric acid or maleic acid, into the pharmaceutical composition to improve the chemical stability of the active ingredient.
Benefits of technology
The addition of a pharmaceutically acceptable organic acid significantly enhances the chemical stability of the pharmaceutical compositions, making them more suitable for oral administration in treating hormonally regulated diseases like prostate cancer and breast cancer.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000002_0001 
Figure IMGF000017_0001 
Figure IMGF000017_0002
Abstract
The present invention relates to a pharmaceutical composition for oral administration, for example in the form of a tablet or a powder suitable to be filled into a capsule shell, comprising 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)- piperidin-4-yl)methoxy)-4H-pyran-4-one (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Compound (I) or a pharmaceutically acceptable salt thereof is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated diseases such as cancer including prostate cancer and breast cancer.
Need to check novelty before this filing date? Find Prior Art